Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 07/22 10:00:15 pm
58.82 USD   +0.05%
07/22 MERCK : Data for Merck's Investigational Once-Daily Formulation of I..
07/21 MERCK ANIMAL HE : Receives FDA Approval of BRAVECTO® (fluralaner top..
07/21 MERCK : Provides Regulatory Update on Biologics Licensing Applicatio..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Lawsuit Claims Merck Overstated Mumps Vaccine Effectiveness

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/22/2012 | 07:32pm CEST
   By Jon Kamp 
 

Two former Merck & Co. Inc. (MRK) employees have sued the company in federal court alleging Merck overstated the effectiveness of a mumps vaccine for which the U.S. government paid hundreds of millions of dollars.

Merck--which stressed that none of these allegations relate to the safety of its product--said the lawsuit is "completely without merit", and that it plans to "vigorously defend itself." The Whitehouse Station, N.J., drug maker also noted that the U.S. Department of Justice has thus far declined to participate in the case after its own two-year probe.

Mumps is a contagious disease that causes symptoms like fever, headache and swollen salivary glands. It was a common illness for kids and young adults before childhood vaccinations became common decades ago, according to the Centers for Disease Control and Prevention, although there were outbreaks in 2006 and 2009. The agency says vaccines are the best way to prevent mumps.

Merck introduced the first vaccine 45 years ago, and since the 1970s it's been part of a combination product that also immunizes children against rubella and measles. According to the lawsuit--filed by former Merck virologists Stephen Krahling and Joan Wlochowski--the company allegedly defrauded the U.S. for more than a decade by hiding the fact the vaccine had become less effective.

As a result, the former employees say the government has long paid for a product that doesn't live up to Merck's claims. The lawsuit seeks a judgment against Merck equal to three times the damages suffered by the U.S., plus the maximum allowable award for the former employees under federal whistleblower laws.

The suit was first filed in 2010 in the U.S. District Court for the Eastern District of Pennsylvania. It was unsealed Thursday after the government declined to get involved in the case.

Merck confirmed Krahling and Wlochowski were former employees, but it said they haven't worked at the company for a decade.

"It's important to understand that none of the allegations in the complaint relate to the safety of M-M-R II"--the vaccine in question--"and we remain confident that M-M-R II helps protect against measles, mumps and rubella as described in the labeling for the vaccine," Merck said in a statement.

"M-M-R II continues to be recommended for routine administration to children by public health authorities around the world, including the U.S. Centers for Disease Control and Prevention and the U.S. Food and Drug Administration," the company said.

Merck doesn't specifically break out sales for the vaccine, but the company reported combined U.S. sales of $1.1 billion last year for that product and two other childhood vaccines. Merck shares recently traded up 1.9% to $40.19 and have risen 6.6% this year.

Write to Jon Kamp at jon.kamp@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
07/22 MERCK : Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (r..
07/21 MERCK ANIMAL HEALTH : Receives FDA Approval of BRAVECTO® (fluralaner topical sol..
07/21 MERCK : Provides Regulatory Update on Biologics Licensing Application for Invest..
07/21 MERCK : Patent Issued for Preparation of Crystalline Forms of Dihydropyrazolopyr..
07/21 MERCK : Findings in Pseudohypoparathyroidism and Genetics Reported from Merck & ..
07/21 MERCK : Findings on Enzymes and Coenzymes Reported by Researchers at Merck & Com..
07/20 U.S. healthcare stock bulls look past political risks
07/19 MERCK : A*STAR and MSD team up to advance peptide therapeutics
07/18DJMARKET SNAPSHOT : Dow On Track For Record Closing High As Tech Rallies
07/18DJGLAXOSMITHKLINE : China's Food and Drug Administration Approves GlaxoSmithKline'..
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/22 OpGen - A Play Against Multiple Antibiotic Resistant Infection Many May Not H..
07/22 Healthcare ratings - upgrades/downgrades
07/21 FDA OKs Merck Animal Health's single-dose flea & tick treatment for dogs and ..
07/21 FDA requests new data on Merck's bezlotoxumab, action date pushed out to Octo..
07/21 BUY GILEAD : 4 Reasons Why
Advertisement
Financials ($)
Sales 2016 39 507 M
EBIT 2016 13 526 M
Net income 2016 6 432 M
Debt 2016 3 946 M
Yield 2016 3,14%
P/E ratio 2016 25,77
P/E ratio 2017 19,77
EV / Sales 2016 4,22x
EV / Sales 2017 4,21x
Capitalization 162 815 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 61,9 $
Spread / Average Target 5,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.11.36%162 815
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.53%219 526
ROCHE HOLDING LTD.-9.55%218 832
BRISTOL-MYERS SQUIBB C..10.02%126 333
More Results